2抑制剂-话题@MedSci

#2抑制剂#

221篇内容 | 4067人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1995574, encodeId=8e4f19955e42b, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, objectType=article, longId=181704, objectId=6557181e048a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6557181e048a, replyNumber=0, likeNumber=128, createdTime=2020-08-21, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6557181e048a, moduleTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6557181e048a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995592, encodeId=708619955927b, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：葡萄糖-钠同向转运体2抑制剂对缺血性心脏病的疗效, objectType=article, longId=190057, objectId=259c19005e1e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=259c19005e1e, replyNumber=0, likeNumber=55, createdTime=2020-11-03, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=259c19005e1e, moduleTitle=Diabetes Obes Metab：葡萄糖-钠同向转运体2抑制剂对缺血性心脏病的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=259c19005e1e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995576, encodeId=f17619955e6a7, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, objectType=article, longId=183195, objectId=6133183195fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6133183195fa, replyNumber=0, likeNumber=59, createdTime=2019-12-20, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6133183195fa, moduleTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6133183195fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995584, encodeId=171d19955844c, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, objectType=article, longId=187245, objectId=3b7518e245e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b7518e245e4, replyNumber=0, likeNumber=57, createdTime=2020-08-30, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b7518e245e4, moduleTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b7518e245e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995575, encodeId=9acb19955e5cb, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=NEJM：口服P2Y12抑制剂基因指导原则, objectType=article, longId=181908, objectId=d6d81819084b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6d81819084b, replyNumber=0, likeNumber=69, createdTime=2020-01-04, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6d81819084b, moduleTitle=NEJM：口服P2Y12抑制剂基因指导原则, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6d81819084b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995563, encodeId=00921995563bd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=慢性心力衰竭：FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格, objectType=article, longId=174322, objectId=0d4b1e4322ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d4b1e4322ee, replyNumber=0, likeNumber=63, createdTime=2019-08-13, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d4b1e4322ee, moduleTitle=慢性心力衰竭：FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d4b1e4322ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995556, encodeId=5a031995556b0, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：钠-葡萄糖共转运蛋白-2抑制剂与癌症, objectType=article, longId=164172, objectId=03b61641e237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03b61641e237, replyNumber=0, likeNumber=61, createdTime=2019-12-02, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03b61641e237, moduleTitle=Diabetes Obes Metab：钠-葡萄糖共转运蛋白-2抑制剂与癌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03b61641e237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995577, encodeId=9db019955e7db, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=SGLT2抑制剂临床应用专家指导建议解读 | CDS2019, objectType=article, longId=183456, objectId=a0c5183456e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0c5183456e9, replyNumber=0, likeNumber=72, createdTime=2020-09-30, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0c5183456e9, moduleTitle=SGLT2抑制剂临床应用专家指导建议解读 | CDS2019, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0c5183456e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995555, encodeId=dcd2199555583, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=美国FDA拒绝了双重SGLT1和SGLT2抑制剂Zynquista治疗1型糖尿病的申请, objectType=article, longId=162858, objectId=f5fa1628585f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5fa1628585f, replyNumber=0, likeNumber=70, createdTime=2019-09-21, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5fa1628585f, moduleTitle=美国FDA拒绝了双重SGLT1和SGLT2抑制剂Zynquista治疗1型糖尿病的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5fa1628585f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995551, encodeId=8fea199555109, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：钠-葡萄糖协同转运蛋白-2抑制剂的使用与下肢截肢风险, objectType=article, longId=159507, objectId=1f6915950e51, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f6915950e51, replyNumber=0, likeNumber=87, createdTime=2019-10-31, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f6915950e51, moduleTitle=Diabetes Obes Metab：钠-葡萄糖协同转运蛋白-2抑制剂的使用与下肢截肢风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f6915950e51)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995578, encodeId=ba7719955e814, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=2019 日本建议：正确使用SGLT-2抑制剂, objectType=article, longId=184705, objectId=d6e2184e05d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6e2184e05d3, replyNumber=0, likeNumber=40, createdTime=2020-01-17, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6e2184e05d3, moduleTitle=2019 日本建议：正确使用SGLT-2抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6e2184e05d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995564, encodeId=60081995564a5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：SGLT2抑制剂与生殖器真菌感染和尿路感染的风险, objectType=article, longId=174707, objectId=386c1e470775, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=386c1e470775, replyNumber=0, likeNumber=76, createdTime=2020-02-22, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=386c1e470775, moduleTitle=Diabetes Obes Metab：SGLT2抑制剂与生殖器真菌感染和尿路感染的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=386c1e470775)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995573, encodeId=e06019955e376, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=阿斯利康的SGLT2抑制剂达格列嗪治疗心力衰竭获得FDA的快速通道认证, objectType=article, longId=179624, objectId=489d1e96248e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=489d1e96248e, replyNumber=0, likeNumber=104, createdTime=2020-03-02, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=489d1e96248e, moduleTitle=阿斯利康的SGLT2抑制剂达格列嗪治疗心力衰竭获得FDA的快速通道认证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=489d1e96248e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995561, encodeId=e54f199556181, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=2019 ADA：阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病, objectType=article, longId=168050, objectId=2d6716805018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6716805018, replyNumber=0, likeNumber=91, createdTime=2019-11-13, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6716805018, moduleTitle=2019 ADA：阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d6716805018)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995566, encodeId=82b619955661c, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Ann Intern Med：钠-葡萄糖协同转运蛋白-2抑制剂与严重尿路感染风险, objectType=article, longId=176938, objectId=84e31e693880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84e31e693880, replyNumber=0, likeNumber=108, createdTime=2020-01-13, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84e31e693880, moduleTitle=Ann Intern Med：钠-葡萄糖协同转运蛋白-2抑制剂与严重尿路感染风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84e31e693880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995560, encodeId=6c431995560b2, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=Diabetes Obes Metab：钠-葡萄糖协同转运蛋白-2抑制剂致急性肾损伤, objectType=article, longId=165428, objectId=392f1654280b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=392f1654280b, replyNumber=0, likeNumber=65, createdTime=2019-10-11, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=392f1654280b, moduleTitle=Diabetes Obes Metab：钠-葡萄糖协同转运蛋白-2抑制剂致急性肾损伤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=392f1654280b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995557, encodeId=8227199555e63, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, objectType=article, longId=164340, objectId=bc7c1643405d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7c1643405d, replyNumber=0, likeNumber=64, createdTime=2020-03-27, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7c1643405d, moduleTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7c1643405d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995567, encodeId=1dbe199556e44, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=AZ的SGLT2抑制剂Forxiga在欧盟扩展用于II型糖尿病, objectType=article, longId=177009, objectId=bd4e1e700904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd4e1e700904, replyNumber=0, likeNumber=87, createdTime=2019-10-27, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd4e1e700904, moduleTitle=AZ的SGLT2抑制剂Forxiga在欧盟扩展用于II型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd4e1e700904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995571, encodeId=4a4919955e1ab, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=NEJM：原发性PCI患者口服P2Y12抑制剂的基因导向策略, objectType=article, longId=178970, objectId=02321e8970bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02321e8970bd, replyNumber=0, likeNumber=105, createdTime=2020-05-01, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02321e8970bd, moduleTitle=NEJM：原发性PCI患者口服P2Y12抑制剂的基因导向策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02321e8970bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1995569, encodeId=90411995569c1, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, objectTitle=SGLT2抑制剂达格列净在心衰研究中显示出益处, objectType=article, longId=178048, objectId=18661e804804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18661e804804, replyNumber=0, likeNumber=72, createdTime=2019-08-27, rootId=0, userName=liuquan, userId=28b7142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18661e804804, moduleTitle=SGLT2抑制剂达格列净在心衰研究中显示出益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18661e804804)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2抑制剂

2020-05-29

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险

2020-08-21

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：葡萄糖-钠同向转运体2抑制剂对缺血性心脏病的疗效

2020-11-03

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善

2019-12-20

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价

2020-08-30

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

NEJM：口服P2Y12抑制剂基因指导原则

2020-01-04

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

慢性心力衰竭：FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格

2019-08-13

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：钠-葡萄糖共转运蛋白-2抑制剂与癌症

2019-12-02

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

SGLT2抑制剂临床应用专家指导建议解读 | CDS2019

2020-09-30

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

美国FDA拒绝了双重SGLT1和SGLT2抑制剂Zynquista治疗1型糖尿病的申请

2019-09-21

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：钠-葡萄糖协同转运蛋白-2抑制剂的使用与下肢截肢风险

2019-10-31

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

2019 日本建议：正确使用SGLT-2抑制剂

2020-01-17

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：SGLT2抑制剂与生殖器真菌感染和尿路感染的风险

2020-02-22

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

阿斯利康的SGLT2抑制剂达格列嗪治疗心力衰竭获得FDA的快速通道认证

2020-03-02

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

2019 ADA：阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病

2019-11-13

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Ann Intern Med：钠-葡萄糖协同转运蛋白-2抑制剂与严重尿路感染风险

2020-01-13

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

Diabetes Obes Metab：钠-葡萄糖协同转运蛋白-2抑制剂致急性肾损伤

2019-10-11

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险

2020-03-27

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

AZ的SGLT2抑制剂Forxiga在欧盟扩展用于II型糖尿病

2019-10-27

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

NEJM：原发性PCI患者口服P2Y12抑制剂的基因导向策略

2020-05-01

liuquan (审核中...)

前往app查看评论内容

#2抑制剂#

SGLT2抑制剂达格列净在心衰研究中显示出益处

2019-08-27

科室
- - 订阅+
  - 更多科室
工具
服务